A peptide's legal status depends on which of six categories it sits in. FDA-approved peptides are the only finished products the FDA has reviewed. Compounding is lawful only when the ingredient qualifies, which rules out BPC-157 and most research peptides today. A “research use only” label does not make a product legal to sell for people, and anti-doping rules apply on top of all of it.
Each category means something specific about who checked the product and what rules it was made under. Tap one to see what it means, who regulates it and the latest FDA action.
The FDA reviewed clinical trial data showing the drug works for a specific use and that its benefits outweigh its risks, then approved a label that states how it is used. This is the only category where the finished product itself has been reviewed.
Federal law, plus the FDA's interim policy, gives a 503A pharmacy four routes to use a bulk ingredient. If a peptide fails all four, there is no lawful pathway, whatever a clinic or website says.
A 503A pharmacy may use it for a patient, but may not regularly make copies of a drug that is on the market.
Semaglutide, tirzepatide, tesamorelinA 503A pharmacy may use it if the bulk ingredient comes from an FDA-registered supplier.
OxytocinA 503A pharmacy may use it.
No research peptide as of October 2026FDA does not generally act against compounding while it reviews the nomination.
Not BPC-157, TB-500, CJC-1295 or ipamorelinThis is where BPC-157, TB-500, CJC-1295, ipamorelin, melanotan II and most research peptides sit as of October 2026. Category 2 substances such as GHRP-2 and kisspeptin-10 end up here too.
"BPC-157 came off Category 2 in April 2026, so pharmacies can make it now."
It came off Category 2 because the people who nominated it withdrew the nomination. That leaves it in no category at all, which is weaker than Category 1. The July 2026 advisory vote recommended adding it to the bulks list, but only a final FDA rule does that. FDA staff had recommended against it, citing a lack of evidence that it works.
FDA places GHRP-2, GHRP-6, ipamorelin, kisspeptin-10, ibutamoren and a group of other peptides, BPC-157 among them, in Category 2.
FDA confirms the tirzepatide shortage is over.
FDA declares the semaglutide shortage over.
Grace periods end for 503A and then 503B compounders making semaglutide copies.
FDA says it will restrict GLP-1 ingredients used in mass-marketed compounded drugs and act on misleading ads.
The FDA list, updated April 22, shows BPC-157, TB-500, CJC-1295 and 14 others as "nominated but withdrawn."
Advisory committee votes 8 to 6, 1 abstaining, to recommend BPC-157 and KPV for the 503A bulks list.
FDA warning letters to five "research use only" peptide sellers.
FDA approval, pharmacy compounding and WADA, side by side. Amber means there is no approved product, no lawful compounding route, or a ban in sport.
Status checked October 13, 2026 against the FDA Category 2 list (current as of April 22, 2026), the FDA shortage announcements and the WADA 2026 Prohibited List. Rules change; each source is linked below.
These substances are prohibited at all times, in and out of competition. The list says each class covers substances with similar structure or effect, so a peptide does not need to be named to be banned.
| Section | What it covers | Peptides named or covered |
|---|---|---|
| S0 Non-approved substances | Any drug not approved for human use by any health authority | BPC-157 (named), retatrutide, melanotan II and other unapproved peptides not listed elsewhere |
| S2.2.1 | Peptides that raise testosterone in males | hCG, LH, gonadorelin, kisspeptin and its analogs |
| S2.2.3 | Growth hormone, analogs and fragments | AOD-9604, hGH 176-191 |
| S2.2.4 | Growth hormone releasing factors | CJC-1295, sermorelin, tesamorelin, ipamorelin, ibutamoren (MK-677), GHRP-2, GHRP-6, hexarelin |
| S2.3 | Growth factors and modulators | Thymosin beta-4 and TB-500, IGF-1 and analogs, mechano growth factors |
| Not listed | Not named on the 2026 list | Semaglutide, tirzepatide, oxytocin |
Ask where the vial comes from. A 503A pharmacy has no lawful ingredient pathway for BPC-157 today, so the product is either compounded outside the rules or bought as a research chemical.
Since the shortages ended, a pharmacy may make it only when your prescriber documents a change you need from the approved product. A cheaper price on its own is not that reason.
WADA bans most healing and growth hormone peptides at all times, and a research-only label does not change that. Check the current list and your federation before using any peptide.
This guide covers US law. Australia, the UK and the EU regulate these products differently, and some peptides approved abroad are not approved in the US.
This guide explains how the rules work. It is not legal advice for any individual, clinic or business.
We email when a final rule, warning letter wave or WADA update changes what this page says. Daily peptide brief, free, no sellers.